Technical Analysis for CCCC - C4 Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 6.47 | -6.23% | -0.43 |
Earnings due: May 2
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
BB Squeeze Ended | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Bollinger Band Squeeze | Range Contraction | -6.23% | |
NR7 | Range Contraction | -6.23% | |
Oversold Stochastic | Weakness | -6.23% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -5.69% | |
Bollinger Band Squeeze | Range Contraction | -5.69% | |
Inside Day | Range Contraction | -5.69% | |
Oversold Stochastic | Weakness | -5.69% | |
New Downtrend | Bearish | -3.72% |
Alert | Time |
---|---|
Down 5% | about 21 hours ago |
Down 3% | about 22 hours ago |
60 Minute Opening Range Breakdown | about 22 hours ago |
10 DMA Resistance | about 22 hours ago |
Down 2 % | about 22 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/02/2024
C4 Therapeutics, Inc. Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Disease Treatment Of Cancer Non Small Cell Lung Cancer Melanoma Colorectal Cancer Multiple Myeloma NSCLC Synovial Sarcoma Treatment Of Various Cancers Peripheral T Cell Lymphoma
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 11.88 |
52 Week Low | 1.06 |
Average Volume | 2,429,926 |
200-Day Moving Average | 4.62 |
50-Day Moving Average | 8.52 |
20-Day Moving Average | 7.41 |
10-Day Moving Average | 6.96 |
Average True Range | 0.51 |
RSI (14) | 31.97 |
ADX | 27.2 |
+DI | 13.55 |
-DI | 30.01 |
Chandelier Exit (Long, 3 ATRs) | 7.03 |
Chandelier Exit (Short, 3 ATRs) | 7.98 |
Upper Bollinger Bands | 8.46 |
Lower Bollinger Band | 6.35 |
Percent B (%b) | 0.06 |
BandWidth | 28.59 |
MACD Line | -0.49 |
MACD Signal Line | -0.43 |
MACD Histogram | -0.0603 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 7.27 | ||||
Resistance 3 (R3) | 7.35 | 7.17 | 7.13 | ||
Resistance 2 (R2) | 7.17 | 6.97 | 7.13 | 7.09 | |
Resistance 1 (R1) | 6.82 | 6.84 | 6.73 | 6.74 | 7.04 |
Pivot Point | 6.64 | 6.64 | 6.60 | 6.60 | 6.64 |
Support 1 (S1) | 6.29 | 6.44 | 6.20 | 6.21 | 5.90 |
Support 2 (S2) | 6.11 | 6.31 | 6.07 | 5.85 | |
Support 3 (S3) | 5.76 | 6.11 | 5.81 | ||
Support 4 (S4) | 5.68 |